Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Mammography | 92 | 2024 | 1030 | 10.400 |
Why?
|
Ultrasonography, Mammary | 38 | 2024 | 383 | 8.630 |
Why?
|
Breast Neoplasms | 137 | 2024 | 16038 | 6.520 |
Why?
|
Breast Diseases | 14 | 2021 | 204 | 4.250 |
Why?
|
Breast | 45 | 2022 | 1361 | 3.490 |
Why?
|
Radiographic Image Enhancement | 18 | 2014 | 406 | 2.440 |
Why?
|
Magnetic Resonance Imaging | 47 | 2024 | 7964 | 2.390 |
Why?
|
Mass Screening | 19 | 2024 | 1568 | 2.250 |
Why?
|
Image-Guided Biopsy | 7 | 2020 | 333 | 1.820 |
Why?
|
Diagnostic Imaging | 7 | 2024 | 1179 | 1.780 |
Why?
|
Biopsy, Needle | 22 | 2019 | 1395 | 1.610 |
Why?
|
Surgical Instruments | 4 | 2023 | 139 | 1.600 |
Why?
|
Cicatrix | 2 | 2024 | 204 | 1.410 |
Why?
|
Image Interpretation, Computer-Assisted | 7 | 2018 | 612 | 1.380 |
Why?
|
Lymph Nodes | 11 | 2023 | 3033 | 1.360 |
Why?
|
Mastectomy, Segmental | 9 | 2021 | 1042 | 1.340 |
Why?
|
Artifacts | 7 | 2023 | 538 | 1.320 |
Why?
|
Triple Negative Breast Neoplasms | 10 | 2024 | 1291 | 1.320 |
Why?
|
Female | 171 | 2024 | 147288 | 1.220 |
Why?
|
Carcinoma, Lobular | 9 | 2024 | 620 | 1.200 |
Why?
|
Lymphatic Metastasis | 13 | 2023 | 4926 | 1.200 |
Why?
|
Carcinoma, Ductal, Breast | 13 | 2018 | 1226 | 1.190 |
Why?
|
Calcinosis | 13 | 2011 | 438 | 1.180 |
Why?
|
Multimodal Imaging | 5 | 2020 | 553 | 1.170 |
Why?
|
Humans | 237 | 2024 | 270732 | 1.100 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 10 | 2020 | 694 | 1.050 |
Why?
|
Biopsy | 13 | 2023 | 3495 | 0.960 |
Why?
|
Early Detection of Cancer | 7 | 2024 | 1336 | 0.950 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 10 | 2013 | 372 | 0.950 |
Why?
|
Archives | 1 | 2024 | 5 | 0.940 |
Why?
|
Breast Carcinoma In Situ | 1 | 2024 | 17 | 0.930 |
Why?
|
Neoadjuvant Therapy | 21 | 2024 | 5113 | 0.890 |
Why?
|
Vascular Neoplasms | 2 | 2023 | 116 | 0.850 |
Why?
|
Radiology Information Systems | 4 | 2015 | 118 | 0.820 |
Why?
|
Hemangioma | 1 | 2023 | 160 | 0.770 |
Why?
|
Contrast Media | 8 | 2020 | 1496 | 0.770 |
Why?
|
Preoperative Care | 6 | 2022 | 1556 | 0.750 |
Why?
|
Mastitis | 1 | 2020 | 11 | 0.750 |
Why?
|
Granulomatous Mastitis | 1 | 2020 | 9 | 0.750 |
Why?
|
Genes, BRCA1 | 3 | 2020 | 395 | 0.730 |
Why?
|
Angiomatosis | 2 | 2021 | 27 | 0.730 |
Why?
|
Breast Neoplasms, Male | 3 | 2018 | 233 | 0.720 |
Why?
|
Retrospective Studies | 46 | 2024 | 39477 | 0.720 |
Why?
|
Hemangiosarcoma | 1 | 2023 | 238 | 0.710 |
Why?
|
Carcinoma, Papillary | 3 | 2018 | 590 | 0.700 |
Why?
|
Radiology | 9 | 2024 | 451 | 0.700 |
Why?
|
Middle Aged | 94 | 2024 | 89569 | 0.670 |
Why?
|
Genes, BRCA2 | 2 | 2020 | 318 | 0.670 |
Why?
|
Neoplasm Staging | 20 | 2024 | 13882 | 0.670 |
Why?
|
Axilla | 7 | 2023 | 915 | 0.660 |
Why?
|
Sensitivity and Specificity | 21 | 2020 | 5121 | 0.650 |
Why?
|
Phyllodes Tumor | 2 | 2018 | 62 | 0.650 |
Why?
|
Diagnosis, Differential | 16 | 2020 | 4862 | 0.640 |
Why?
|
Vulnerable Populations | 1 | 2020 | 194 | 0.630 |
Why?
|
Hyperplasia | 6 | 2021 | 567 | 0.630 |
Why?
|
Machine Learning | 1 | 2021 | 357 | 0.620 |
Why?
|
Adult | 84 | 2024 | 80724 | 0.610 |
Why?
|
Image Enhancement | 4 | 2017 | 568 | 0.600 |
Why?
|
Gadolinium DTPA | 1 | 2018 | 171 | 0.590 |
Why?
|
Stereotaxic Techniques | 3 | 2017 | 185 | 0.570 |
Why?
|
Ultrasonography, Interventional | 2 | 2018 | 451 | 0.560 |
Why?
|
Breast Density | 1 | 2016 | 19 | 0.550 |
Why?
|
Ultrasonography | 19 | 2023 | 1925 | 0.550 |
Why?
|
Foreign-Body Migration | 1 | 2017 | 119 | 0.530 |
Why?
|
Aged | 63 | 2024 | 72928 | 0.530 |
Why?
|
Molecular Imaging | 1 | 2017 | 187 | 0.510 |
Why?
|
Positron Emission Tomography Computed Tomography | 1 | 2020 | 858 | 0.490 |
Why?
|
Imaging, Three-Dimensional | 5 | 2014 | 949 | 0.470 |
Why?
|
Mobile Health Units | 1 | 2013 | 35 | 0.460 |
Why?
|
Congresses as Topic | 1 | 2015 | 314 | 0.450 |
Why?
|
Radiography | 23 | 2024 | 1944 | 0.430 |
Why?
|
Radiographic Magnification | 3 | 2009 | 14 | 0.430 |
Why?
|
Cone-Beam Computed Tomography | 3 | 2009 | 205 | 0.420 |
Why?
|
Tomography, X-Ray Computed | 32 | 2020 | 7747 | 0.420 |
Why?
|
Formative Feedback | 2 | 2023 | 34 | 0.420 |
Why?
|
X-Ray Film | 2 | 2009 | 31 | 0.410 |
Why?
|
Algorithms | 10 | 2011 | 3982 | 0.410 |
Why?
|
Subtraction Technique | 2 | 2002 | 142 | 0.400 |
Why?
|
Workload | 2 | 2013 | 202 | 0.400 |
Why?
|
Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2013 | 168 | 0.390 |
Why?
|
Guideline Adherence | 2 | 2017 | 653 | 0.390 |
Why?
|
Magnetic Resonance Imaging, Interventional | 1 | 2012 | 106 | 0.390 |
Why?
|
Osteosarcoma | 1 | 2019 | 950 | 0.390 |
Why?
|
Observer Variation | 10 | 2014 | 710 | 0.380 |
Why?
|
Attitude of Health Personnel | 3 | 2015 | 957 | 0.380 |
Why?
|
Biopsy, Large-Core Needle | 3 | 2020 | 140 | 0.370 |
Why?
|
Papilloma, Intraductal | 2 | 2020 | 17 | 0.370 |
Why?
|
Patient Selection | 3 | 2018 | 2117 | 0.360 |
Why?
|
Elasticity Imaging Techniques | 1 | 2013 | 189 | 0.360 |
Why?
|
Efficiency, Organizational | 2 | 2009 | 91 | 0.360 |
Why?
|
Monitoring, Intraoperative | 1 | 2011 | 266 | 0.350 |
Why?
|
Liver Neoplasms | 5 | 2020 | 4773 | 0.350 |
Why?
|
Ultrasonography, Doppler, Color | 2 | 2007 | 102 | 0.350 |
Why?
|
ROC Curve | 13 | 2024 | 1219 | 0.340 |
Why?
|
Fibroma | 2 | 2006 | 88 | 0.330 |
Why?
|
Radiologists | 3 | 2022 | 178 | 0.320 |
Why?
|
Fat Necrosis | 1 | 2009 | 64 | 0.320 |
Why?
|
Task Performance and Analysis | 1 | 2009 | 142 | 0.310 |
Why?
|
Pregnancy Complications, Neoplastic | 2 | 2007 | 227 | 0.310 |
Why?
|
Precancerous Conditions | 3 | 2011 | 1079 | 0.310 |
Why?
|
Artificial Intelligence | 2 | 2024 | 430 | 0.300 |
Why?
|
Sentinel Lymph Node Biopsy | 4 | 2021 | 1444 | 0.300 |
Why?
|
Monte Carlo Method | 3 | 2009 | 694 | 0.280 |
Why?
|
Lymphoma, B-Cell | 3 | 2011 | 924 | 0.280 |
Why?
|
Phantoms, Imaging | 9 | 2023 | 1315 | 0.280 |
Why?
|
Chondroblastoma | 1 | 2006 | 14 | 0.270 |
Why?
|
Follow-Up Studies | 11 | 2021 | 15195 | 0.270 |
Why?
|
Ilium | 1 | 2006 | 55 | 0.270 |
Why?
|
Inflammatory Breast Neoplasms | 2 | 2023 | 511 | 0.260 |
Why?
|
Mammary Glands, Human | 2 | 2008 | 183 | 0.260 |
Why?
|
Sacrum | 1 | 2006 | 135 | 0.250 |
Why?
|
Reproducibility of Results | 14 | 2013 | 6195 | 0.250 |
Why?
|
Fibromatosis, Aggressive | 2 | 2004 | 110 | 0.250 |
Why?
|
Lipoma | 2 | 2004 | 88 | 0.250 |
Why?
|
Clinical Competence | 5 | 2021 | 1369 | 0.250 |
Why?
|
Aortic Rupture | 2 | 1996 | 117 | 0.250 |
Why?
|
Spirituality | 1 | 2006 | 129 | 0.250 |
Why?
|
Liposarcoma | 2 | 2000 | 244 | 0.240 |
Why?
|
Radius | 1 | 2024 | 43 | 0.240 |
Why?
|
Mesentery | 1 | 2004 | 73 | 0.230 |
Why?
|
Scotland | 1 | 2024 | 38 | 0.230 |
Why?
|
Mastectomy | 5 | 2022 | 1558 | 0.230 |
Why?
|
Prospective Studies | 10 | 2023 | 13302 | 0.230 |
Why?
|
Diagnosis, Computer-Assisted | 4 | 2013 | 165 | 0.220 |
Why?
|
Positron-Emission Tomography | 5 | 2020 | 2210 | 0.220 |
Why?
|
Aged, 80 and over | 20 | 2024 | 30822 | 0.220 |
Why?
|
Adenocarcinoma | 3 | 2020 | 7909 | 0.220 |
Why?
|
Diffusion Magnetic Resonance Imaging | 3 | 2022 | 348 | 0.210 |
Why?
|
Personnel Selection | 1 | 2024 | 89 | 0.210 |
Why?
|
Practice Guidelines as Topic | 4 | 2017 | 2494 | 0.210 |
Why?
|
Practice Patterns, Physicians' | 5 | 2017 | 1347 | 0.210 |
Why?
|
Intestinal Neoplasms | 1 | 2004 | 197 | 0.210 |
Why?
|
Radiography, Thoracic | 3 | 2002 | 461 | 0.200 |
Why?
|
Radiography, Dual-Energy Scanned Projection | 1 | 2002 | 54 | 0.200 |
Why?
|
Communication | 2 | 2021 | 907 | 0.200 |
Why?
|
Aortic Aneurysm, Abdominal | 2 | 1996 | 393 | 0.200 |
Why?
|
Fluorodeoxyglucose F18 | 3 | 2020 | 1253 | 0.200 |
Why?
|
Radiation Dosage | 6 | 2014 | 1025 | 0.200 |
Why?
|
Adenoma | 2 | 2004 | 732 | 0.200 |
Why?
|
Skin Neoplasms | 1 | 2018 | 4778 | 0.190 |
Why?
|
Phthalazines | 2 | 2022 | 261 | 0.190 |
Why?
|
Mentoring | 1 | 2022 | 95 | 0.190 |
Why?
|
Chi-Square Distribution | 2 | 2015 | 1353 | 0.180 |
Why?
|
United States | 10 | 2024 | 16332 | 0.180 |
Why?
|
Pyelonephritis | 2 | 1995 | 39 | 0.180 |
Why?
|
Leiomyoma | 1 | 2001 | 156 | 0.180 |
Why?
|
Esthetics | 1 | 2021 | 198 | 0.180 |
Why?
|
Lung Diseases | 4 | 1999 | 744 | 0.180 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 12 | 2023 | 16274 | 0.170 |
Why?
|
Learning | 1 | 2023 | 421 | 0.170 |
Why?
|
Fellowships and Scholarships | 1 | 2024 | 413 | 0.170 |
Why?
|
Mediastinal Neoplasms | 2 | 2000 | 427 | 0.170 |
Why?
|
Nipple Discharge | 1 | 2019 | 8 | 0.170 |
Why?
|
Whole Body Imaging | 1 | 2020 | 114 | 0.170 |
Why?
|
Margins of Excision | 1 | 2021 | 297 | 0.170 |
Why?
|
Emphysema | 2 | 1995 | 87 | 0.170 |
Why?
|
Feasibility Studies | 6 | 2017 | 2363 | 0.170 |
Why?
|
Advisory Committees | 1 | 2020 | 217 | 0.160 |
Why?
|
Oncolytic Virotherapy | 1 | 2021 | 257 | 0.160 |
Why?
|
Bone Neoplasms | 2 | 2015 | 2652 | 0.160 |
Why?
|
Male | 46 | 2020 | 127646 | 0.160 |
Why?
|
Chemotherapy, Adjuvant | 9 | 2023 | 3962 | 0.160 |
Why?
|
Prognosis | 15 | 2022 | 22256 | 0.160 |
Why?
|
Hamartoma | 1 | 1999 | 117 | 0.160 |
Why?
|
Biological Products | 1 | 2021 | 309 | 0.150 |
Why?
|
Response Evaluation Criteria in Solid Tumors | 1 | 2018 | 161 | 0.150 |
Why?
|
Area Under Curve | 3 | 2013 | 720 | 0.150 |
Why?
|
Data Display | 3 | 2013 | 49 | 0.150 |
Why?
|
Peritoneal Neoplasms | 1 | 2004 | 835 | 0.150 |
Why?
|
Vacuum | 3 | 2012 | 42 | 0.150 |
Why?
|
Connecticut | 1 | 2016 | 34 | 0.140 |
Why?
|
Uterine Neoplasms | 1 | 2001 | 566 | 0.140 |
Why?
|
Periodicals as Topic | 1 | 2021 | 340 | 0.140 |
Why?
|
Paclitaxel | 4 | 2020 | 2056 | 0.140 |
Why?
|
Minimally Invasive Surgical Procedures | 1 | 1999 | 531 | 0.130 |
Why?
|
Antineoplastic Agents | 2 | 2018 | 14503 | 0.130 |
Why?
|
Tumor Burden | 2 | 2021 | 2019 | 0.130 |
Why?
|
Treatment Outcome | 13 | 2024 | 34225 | 0.130 |
Why?
|
Kidney | 5 | 1996 | 2199 | 0.130 |
Why?
|
Fluorouracil | 4 | 2020 | 1967 | 0.130 |
Why?
|
Decision Making | 2 | 2016 | 1346 | 0.130 |
Why?
|
Surveys and Questionnaires | 7 | 2024 | 5937 | 0.130 |
Why?
|
Retroperitoneal Fibrosis | 1 | 1995 | 6 | 0.130 |
Why?
|
Lymph Node Excision | 4 | 2022 | 2021 | 0.130 |
Why?
|
Coronary Disease | 1 | 1999 | 811 | 0.120 |
Why?
|
Neoplasm Invasiveness | 4 | 2018 | 4065 | 0.120 |
Why?
|
Sentinel Lymph Node | 1 | 2017 | 222 | 0.120 |
Why?
|
Quality Assurance, Health Care | 1 | 1999 | 603 | 0.120 |
Why?
|
Age Distribution | 2 | 2015 | 715 | 0.120 |
Why?
|
Incidental Findings | 1 | 2016 | 285 | 0.120 |
Why?
|
Nephroma, Mesoblastic | 1 | 1994 | 11 | 0.120 |
Why?
|
Image Processing, Computer-Assisted | 2 | 2015 | 1700 | 0.120 |
Why?
|
Coronary Artery Bypass | 1 | 1999 | 753 | 0.120 |
Why?
|
Genetic Therapy | 1 | 2021 | 1630 | 0.110 |
Why?
|
Cost-Benefit Analysis | 2 | 2013 | 982 | 0.110 |
Why?
|
Urinary Bladder Diseases | 1 | 1994 | 51 | 0.110 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2017 | 556 | 0.110 |
Why?
|
Health Care Surveys | 1 | 2015 | 446 | 0.110 |
Why?
|
Retroperitoneal Neoplasms | 2 | 1994 | 293 | 0.110 |
Why?
|
Combined Modality Therapy | 8 | 2021 | 9008 | 0.110 |
Why?
|
Physical Examination | 1 | 2015 | 302 | 0.110 |
Why?
|
Guidelines as Topic | 1 | 2015 | 382 | 0.110 |
Why?
|
Cancer Care Facilities | 1 | 2018 | 905 | 0.110 |
Why?
|
Appointments and Schedules | 1 | 2013 | 97 | 0.110 |
Why?
|
Lymphoma, Non-Hodgkin | 2 | 1996 | 1053 | 0.110 |
Why?
|
Neoplasm Recurrence, Local | 7 | 2022 | 10258 | 0.110 |
Why?
|
Texas | 2 | 2018 | 6464 | 0.110 |
Why?
|
Trastuzumab | 1 | 2015 | 718 | 0.110 |
Why?
|
Cyclophosphamide | 4 | 2020 | 3145 | 0.100 |
Why?
|
Databases, Factual | 2 | 2018 | 2302 | 0.100 |
Why?
|
Computer Simulation | 3 | 2009 | 1576 | 0.100 |
Why?
|
Risk Factors | 3 | 2024 | 18241 | 0.100 |
Why?
|
Mammaplasty | 2 | 2015 | 791 | 0.100 |
Why?
|
Forecasting | 2 | 2013 | 705 | 0.100 |
Why?
|
Survival Rate | 6 | 2018 | 12448 | 0.100 |
Why?
|
X-Ray Intensifying Screens | 3 | 2006 | 33 | 0.100 |
Why?
|
Scattering, Radiation | 2 | 2009 | 329 | 0.100 |
Why?
|
Feedback | 2 | 2023 | 217 | 0.100 |
Why?
|
Receptor, ErbB-2 | 3 | 2023 | 2615 | 0.100 |
Why?
|
Radiopharmaceuticals | 3 | 2013 | 1335 | 0.100 |
Why?
|
Carcinoma in Situ | 3 | 2010 | 496 | 0.100 |
Why?
|
Premedication | 1 | 1991 | 133 | 0.100 |
Why?
|
Kidney Neoplasms | 3 | 1997 | 3109 | 0.090 |
Why?
|
Endometriosis | 1 | 1994 | 240 | 0.090 |
Why?
|
Time Factors | 7 | 2010 | 13258 | 0.090 |
Why?
|
Tamoxifen | 1 | 1995 | 883 | 0.090 |
Why?
|
Doxorubicin | 4 | 2007 | 3059 | 0.090 |
Why?
|
Pregnancy | 4 | 2015 | 7823 | 0.090 |
Why?
|
False Negative Reactions | 3 | 2017 | 282 | 0.090 |
Why?
|
Early Diagnosis | 1 | 2011 | 311 | 0.090 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2015 | 846 | 0.090 |
Why?
|
Receptors, Progesterone | 2 | 2018 | 1415 | 0.090 |
Why?
|
Pilot Projects | 3 | 2022 | 2866 | 0.090 |
Why?
|
Spondylitis, Ankylosing | 1 | 1989 | 31 | 0.090 |
Why?
|
Prostheses and Implants | 2 | 2007 | 302 | 0.090 |
Why?
|
Internship and Residency | 1 | 2021 | 1478 | 0.090 |
Why?
|
Erythropoietin | 1 | 1991 | 211 | 0.090 |
Why?
|
Pattern Recognition, Automated | 1 | 2010 | 128 | 0.090 |
Why?
|
Pandemics | 3 | 2024 | 1625 | 0.080 |
Why?
|
Multiple Sclerosis | 2 | 1990 | 367 | 0.080 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 869 | 0.080 |
Why?
|
Escherichia coli Infections | 2 | 1996 | 259 | 0.080 |
Why?
|
Lung | 7 | 2002 | 3247 | 0.080 |
Why?
|
Aortic Aneurysm | 1 | 1991 | 232 | 0.080 |
Why?
|
Receptors, Estrogen | 2 | 2018 | 2118 | 0.080 |
Why?
|
Program Evaluation | 2 | 2022 | 625 | 0.080 |
Why?
|
Radiography, Interventional | 3 | 1999 | 316 | 0.080 |
Why?
|
Software | 3 | 2010 | 1354 | 0.080 |
Why?
|
Methotrexate | 1 | 2011 | 1024 | 0.080 |
Why?
|
X-Rays | 4 | 2009 | 148 | 0.070 |
Why?
|
User-Computer Interface | 1 | 2009 | 289 | 0.070 |
Why?
|
Professional Competence | 1 | 2009 | 142 | 0.070 |
Why?
|
Interferon-alpha | 1 | 1992 | 905 | 0.070 |
Why?
|
Linear Models | 1 | 2010 | 1103 | 0.070 |
Why?
|
Biopsy, Fine-Needle | 1 | 2010 | 699 | 0.070 |
Why?
|
Tomography, Spiral Computed | 1 | 2007 | 133 | 0.070 |
Why?
|
Radionuclide Imaging | 1 | 2008 | 658 | 0.070 |
Why?
|
Immunohistochemistry | 1 | 2018 | 7703 | 0.070 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 2 | 2022 | 1007 | 0.070 |
Why?
|
Cohort Studies | 4 | 2015 | 9480 | 0.070 |
Why?
|
Scrotum | 2 | 2004 | 57 | 0.070 |
Why?
|
Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2022 | 505 | 0.070 |
Why?
|
Rituximab | 1 | 2011 | 1559 | 0.070 |
Why?
|
Genes, p53 | 1 | 2011 | 1123 | 0.070 |
Why?
|
Medical Staff, Hospital | 1 | 2006 | 119 | 0.070 |
Why?
|
Mutation | 2 | 2020 | 15636 | 0.070 |
Why?
|
Dilatation, Pathologic | 1 | 2005 | 91 | 0.060 |
Why?
|
Germ-Line Mutation | 2 | 2022 | 1084 | 0.060 |
Why?
|
Young Adult | 4 | 2021 | 22164 | 0.060 |
Why?
|
Anemia | 1 | 1991 | 721 | 0.060 |
Why?
|
Cytarabine | 1 | 2011 | 1993 | 0.060 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2011 | 1329 | 0.060 |
Why?
|
Genomics | 1 | 2016 | 2815 | 0.060 |
Why?
|
Genital Diseases, Male | 1 | 2004 | 28 | 0.060 |
Why?
|
Histiocytosis, Sinus | 1 | 2005 | 88 | 0.060 |
Why?
|
Myoma | 1 | 2004 | 9 | 0.060 |
Why?
|
Epidermal Cyst | 1 | 2004 | 46 | 0.060 |
Why?
|
Leukemic Infiltration | 1 | 2004 | 73 | 0.060 |
Why?
|
Terminology as Topic | 1 | 2006 | 427 | 0.060 |
Why?
|
Urography | 2 | 1994 | 44 | 0.060 |
Why?
|
Risk Assessment | 3 | 2016 | 7153 | 0.060 |
Why?
|
Contrast Sensitivity | 2 | 2013 | 61 | 0.060 |
Why?
|
Education, Distance | 1 | 2024 | 100 | 0.050 |
Why?
|
Drainage | 1 | 1995 | 429 | 0.050 |
Why?
|
Asbestosis | 1 | 2002 | 8 | 0.050 |
Why?
|
Necrosis | 2 | 2020 | 597 | 0.050 |
Why?
|
Ergonomics | 1 | 2022 | 28 | 0.050 |
Why?
|
Administration, Oral | 2 | 2019 | 1581 | 0.050 |
Why?
|
Lymphangioma, Cystic | 1 | 2001 | 22 | 0.050 |
Why?
|
Esthesioneuroblastoma, Olfactory | 1 | 2003 | 113 | 0.050 |
Why?
|
Pleural Diseases | 1 | 2002 | 58 | 0.050 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 2 | 2009 | 2428 | 0.050 |
Why?
|
Adolescent | 3 | 2018 | 32336 | 0.050 |
Why?
|
Herpesvirus 1, Human | 1 | 2021 | 111 | 0.050 |
Why?
|
Staining and Labeling | 1 | 2022 | 431 | 0.050 |
Why?
|
Phenotype | 3 | 2018 | 6400 | 0.050 |
Why?
|
Leukemia, Promyelocytic, Acute | 1 | 2004 | 439 | 0.050 |
Why?
|
Faculty, Medical | 1 | 2024 | 318 | 0.050 |
Why?
|
Breast Implants | 2 | 2015 | 407 | 0.050 |
Why?
|
Epirubicin | 1 | 2020 | 157 | 0.050 |
Why?
|
Intestine, Small | 1 | 2004 | 514 | 0.050 |
Why?
|
Ketones | 1 | 2020 | 57 | 0.050 |
Why?
|
Postoperative Complications | 2 | 2015 | 5811 | 0.050 |
Why?
|
Furans | 1 | 2020 | 106 | 0.050 |
Why?
|
Nose Neoplasms | 1 | 2003 | 234 | 0.050 |
Why?
|
Disease-Free Survival | 3 | 2022 | 10095 | 0.050 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2006 | 2729 | 0.040 |
Why?
|
Lymphocyte Count | 1 | 2021 | 489 | 0.040 |
Why?
|
Pneumonia | 2 | 2004 | 761 | 0.040 |
Why?
|
Hepatic Artery | 1 | 2001 | 250 | 0.040 |
Why?
|
Calibration | 2 | 2012 | 339 | 0.040 |
Why?
|
Thymoma | 1 | 2003 | 250 | 0.040 |
Why?
|
Mentors | 1 | 2022 | 217 | 0.040 |
Why?
|
Fluorescent Antibody Technique | 1 | 2022 | 1079 | 0.040 |
Why?
|
Epididymis | 2 | 1997 | 69 | 0.040 |
Why?
|
Practice Management | 1 | 1999 | 10 | 0.040 |
Why?
|
False Positive Reactions | 2 | 2012 | 361 | 0.040 |
Why?
|
Predictive Value of Tests | 3 | 2016 | 5022 | 0.040 |
Why?
|
Biomarkers, Tumor | 3 | 2017 | 10633 | 0.040 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2004 | 881 | 0.040 |
Why?
|
Carcinoma, Renal Cell | 1 | 1992 | 2399 | 0.040 |
Why?
|
Computer Communication Networks | 1 | 1999 | 44 | 0.040 |
Why?
|
Medical Oncology | 1 | 2008 | 1470 | 0.040 |
Why?
|
Technology, Radiologic | 1 | 1999 | 80 | 0.040 |
Why?
|
Anthracyclines | 1 | 2021 | 332 | 0.040 |
Why?
|
Immobilization | 1 | 1999 | 95 | 0.040 |
Why?
|
Computer Systems | 1 | 1999 | 109 | 0.040 |
Why?
|
Accreditation | 1 | 2019 | 139 | 0.040 |
Why?
|
Thymus Neoplasms | 1 | 2003 | 413 | 0.040 |
Why?
|
T-Lymphocyte Subsets | 1 | 2021 | 592 | 0.040 |
Why?
|
Health Care Rationing | 1 | 1999 | 92 | 0.040 |
Why?
|
Fluoroscopy | 1 | 1999 | 234 | 0.040 |
Why?
|
Workplace | 1 | 1999 | 90 | 0.040 |
Why?
|
Models, Biological | 2 | 2008 | 3253 | 0.040 |
Why?
|
Efficiency | 2 | 2008 | 96 | 0.040 |
Why?
|
Radiation Injuries | 2 | 2003 | 1449 | 0.040 |
Why?
|
Neoplasm, Residual | 4 | 2007 | 1716 | 0.040 |
Why?
|
Parathyroid Neoplasms | 1 | 1999 | 186 | 0.040 |
Why?
|
Technetium | 1 | 2017 | 77 | 0.040 |
Why?
|
Cauda Equina | 1 | 1997 | 12 | 0.040 |
Why?
|
Taxoids | 1 | 2021 | 994 | 0.040 |
Why?
|
Mastectomy, Simple | 1 | 2017 | 58 | 0.040 |
Why?
|
BRCA2 Protein | 1 | 2019 | 375 | 0.040 |
Why?
|
Rosaniline Dyes | 1 | 2017 | 109 | 0.040 |
Why?
|
Adenoma, Villous | 1 | 1996 | 10 | 0.040 |
Why?
|
Immunophenotyping | 1 | 2021 | 1701 | 0.040 |
Why?
|
Telangiectasia, Hereditary Hemorrhagic | 1 | 1996 | 8 | 0.040 |
Why?
|
Lymphoid Tissue | 1 | 1997 | 96 | 0.040 |
Why?
|
Fournier Gangrene | 1 | 1996 | 5 | 0.030 |
Why?
|
Internet | 1 | 2021 | 729 | 0.030 |
Why?
|
Peroneal Nerve | 1 | 1996 | 6 | 0.030 |
Why?
|
Remission Induction | 2 | 2015 | 3621 | 0.030 |
Why?
|
Peripheral Nervous System Neoplasms | 1 | 1997 | 72 | 0.030 |
Why?
|
Fallopian Tube Neoplasms | 1 | 1997 | 153 | 0.030 |
Why?
|
Preoperative Period | 1 | 2017 | 344 | 0.030 |
Why?
|
Cholangitis | 1 | 1996 | 49 | 0.030 |
Why?
|
Research Design | 1 | 2024 | 1595 | 0.030 |
Why?
|
Arteriovenous Malformations | 1 | 1996 | 71 | 0.030 |
Why?
|
BRCA1 Protein | 1 | 2019 | 518 | 0.030 |
Why?
|
Pyelonephritis, Xanthogranulomatous | 1 | 1995 | 1 | 0.030 |
Why?
|
Lung Neoplasms | 2 | 2015 | 11816 | 0.030 |
Why?
|
Fasciitis, Necrotizing | 1 | 1996 | 37 | 0.030 |
Why?
|
Aspergillus fumigatus | 1 | 1996 | 138 | 0.030 |
Why?
|
Adenoma, Liver Cell | 1 | 1995 | 17 | 0.030 |
Why?
|
Canada | 1 | 2017 | 446 | 0.030 |
Why?
|
Adenocarcinoma, Mucinous | 1 | 1999 | 442 | 0.030 |
Why?
|
Programmed Cell Death 1 Receptor | 1 | 2022 | 1069 | 0.030 |
Why?
|
Age Factors | 4 | 1999 | 5500 | 0.030 |
Why?
|
Hepatitis | 1 | 1996 | 93 | 0.030 |
Why?
|
Orbital Diseases | 1 | 1996 | 116 | 0.030 |
Why?
|
Lung Diseases, Fungal | 1 | 1996 | 124 | 0.030 |
Why?
|
B7-H1 Antigen | 1 | 2022 | 1057 | 0.030 |
Why?
|
Curriculum | 1 | 2021 | 905 | 0.030 |
Why?
|
Epididymitis | 1 | 1995 | 2 | 0.030 |
Why?
|
Thoracic Diseases | 1 | 1995 | 33 | 0.030 |
Why?
|
Mucormycosis | 1 | 1996 | 110 | 0.030 |
Why?
|
Esophageal Neoplasms | 1 | 1989 | 3241 | 0.030 |
Why?
|
Intraoperative Period | 2 | 2007 | 253 | 0.030 |
Why?
|
Rhabdomyosarcoma, Embryonal | 1 | 1996 | 77 | 0.030 |
Why?
|
Captopril | 1 | 1994 | 35 | 0.030 |
Why?
|
Opportunistic Infections | 1 | 1996 | 226 | 0.030 |
Why?
|
Pneumonia, Pneumocystis | 1 | 1995 | 68 | 0.030 |
Why?
|
Vasculitis, Leukocytoclastic, Cutaneous | 1 | 1994 | 19 | 0.030 |
Why?
|
Oropharynx | 1 | 1994 | 76 | 0.030 |
Why?
|
Tacrolimus | 1 | 1996 | 347 | 0.030 |
Why?
|
Aspergillosis | 1 | 1996 | 246 | 0.030 |
Why?
|
Pulmonary Veins | 1 | 1996 | 182 | 0.030 |
Why?
|
Medication Adherence | 1 | 2019 | 520 | 0.030 |
Why?
|
Cysts | 1 | 1996 | 202 | 0.030 |
Why?
|
Duodenal Diseases | 1 | 1994 | 44 | 0.030 |
Why?
|
Vasculitis | 1 | 1994 | 68 | 0.030 |
Why?
|
Eosinophilic Granuloma | 1 | 1993 | 13 | 0.030 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 1995 | 163 | 0.030 |
Why?
|
Sarcoidosis | 1 | 1995 | 113 | 0.030 |
Why?
|
Diaphragm | 1 | 1995 | 184 | 0.030 |
Why?
|
Neurilemmoma | 1 | 1994 | 128 | 0.030 |
Why?
|
Cystoscopy | 1 | 1994 | 89 | 0.030 |
Why?
|
Abscess | 1 | 1995 | 178 | 0.030 |
Why?
|
Equipment Failure Analysis | 2 | 2006 | 334 | 0.030 |
Why?
|
Kidney Diseases, Cystic | 1 | 1993 | 61 | 0.030 |
Why?
|
Testicular Neoplasms | 1 | 1997 | 554 | 0.030 |
Why?
|
Liquid Crystals | 1 | 2012 | 3 | 0.030 |
Why?
|
Silicone Elastomers | 1 | 1993 | 47 | 0.030 |
Why?
|
Lymphoproliferative Disorders | 1 | 1995 | 371 | 0.030 |
Why?
|
Solitary Pulmonary Nodule | 1 | 1994 | 125 | 0.030 |
Why?
|
Colitis | 1 | 1996 | 338 | 0.030 |
Why?
|
Trachea | 1 | 1994 | 271 | 0.030 |
Why?
|
Models, Statistical | 2 | 2009 | 1202 | 0.030 |
Why?
|
Neoplasm Grading | 1 | 2017 | 1810 | 0.030 |
Why?
|
Echo-Planar Imaging | 1 | 1993 | 73 | 0.030 |
Why?
|
Amyloidosis | 1 | 1994 | 179 | 0.030 |
Why?
|
Hypertrophy | 1 | 1992 | 164 | 0.030 |
Why?
|
Pulmonary Artery | 1 | 1996 | 522 | 0.030 |
Why?
|
Pheochromocytoma | 1 | 1995 | 298 | 0.030 |
Why?
|
Floxuridine | 1 | 1992 | 38 | 0.030 |
Why?
|
Length of Stay | 1 | 1999 | 2029 | 0.030 |
Why?
|
Gene Expression Profiling | 1 | 2004 | 5241 | 0.030 |
Why?
|
Graft Rejection | 1 | 1996 | 846 | 0.020 |
Why?
|
Signal-To-Noise Ratio | 1 | 2011 | 123 | 0.020 |
Why?
|
Injections, Subcutaneous | 1 | 1992 | 345 | 0.020 |
Why?
|
Tumor Microenvironment | 1 | 2022 | 2976 | 0.020 |
Why?
|
Reference Standards | 1 | 2012 | 360 | 0.020 |
Why?
|
Thoracic Neoplasms | 1 | 1994 | 343 | 0.020 |
Why?
|
Lung Transplantation | 1 | 1995 | 385 | 0.020 |
Why?
|
Leucovorin | 1 | 1992 | 340 | 0.020 |
Why?
|
Religion and Medicine | 1 | 1991 | 48 | 0.020 |
Why?
|
Neuroblastoma | 1 | 1997 | 695 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2012 | 769 | 0.020 |
Why?
|
Syringomyelia | 1 | 1990 | 19 | 0.020 |
Why?
|
Kidney Transplantation | 1 | 1996 | 786 | 0.020 |
Why?
|
HLA-B27 Antigen | 1 | 1989 | 11 | 0.020 |
Why?
|
Paraffin | 1 | 2009 | 13 | 0.020 |
Why?
|
Intubation, Intratracheal | 1 | 1994 | 458 | 0.020 |
Why?
|
Hysterectomy | 1 | 1994 | 644 | 0.020 |
Why?
|
Biomarkers | 1 | 2021 | 5174 | 0.020 |
Why?
|
Cystectomy | 1 | 1994 | 634 | 0.020 |
Why?
|
Immunosuppressive Agents | 1 | 1996 | 1431 | 0.020 |
Why?
|
Analysis of Variance | 1 | 2013 | 2327 | 0.020 |
Why?
|
Brain | 1 | 2003 | 4198 | 0.020 |
Why?
|
Infusions, Intravenous | 1 | 1992 | 1410 | 0.020 |
Why?
|
Medicare | 1 | 2014 | 928 | 0.020 |
Why?
|
Calcification, Physiologic | 1 | 2008 | 53 | 0.020 |
Why?
|
Colonic Neoplasms | 1 | 1996 | 1429 | 0.020 |
Why?
|
Surgical Flaps | 1 | 2015 | 959 | 0.020 |
Why?
|
Muscle, Skeletal | 1 | 1996 | 1328 | 0.020 |
Why?
|
Radiotherapy | 1 | 2015 | 1852 | 0.020 |
Why?
|
Clavicle | 1 | 2007 | 65 | 0.020 |
Why?
|
Immunotherapy | 1 | 2021 | 3479 | 0.020 |
Why?
|
Gene Expression | 1 | 2016 | 3591 | 0.020 |
Why?
|
Physicians | 1 | 1996 | 913 | 0.020 |
Why?
|
Decision Support Systems, Clinical | 1 | 2011 | 257 | 0.020 |
Why?
|
Quality of Life | 1 | 2022 | 4721 | 0.020 |
Why?
|
Liver Transplantation | 1 | 1996 | 1159 | 0.020 |
Why?
|
Neoplasm Metastasis | 2 | 2001 | 5241 | 0.020 |
Why?
|
Recurrence | 3 | 2004 | 4876 | 0.020 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 1997 | 1701 | 0.020 |
Why?
|
Aorta, Thoracic | 1 | 1991 | 573 | 0.020 |
Why?
|
Equipment Design | 1 | 2009 | 1230 | 0.020 |
Why?
|
Glioma | 1 | 1997 | 2001 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2013 | 5026 | 0.020 |
Why?
|
Recombinant Proteins | 1 | 1991 | 2933 | 0.020 |
Why?
|
Calcium Carbonate | 1 | 2005 | 29 | 0.020 |
Why?
|
Child, Preschool | 2 | 1999 | 16759 | 0.020 |
Why?
|
Punctures | 1 | 1995 | 109 | 0.020 |
Why?
|
Bronchi | 2 | 1997 | 327 | 0.020 |
Why?
|
Specimen Handling | 1 | 2006 | 304 | 0.020 |
Why?
|
HIV Infections | 1 | 1997 | 2225 | 0.010 |
Why?
|
Treatment Failure | 1 | 2007 | 1432 | 0.010 |
Why?
|
Pancreatic Neoplasms | 1 | 2001 | 5235 | 0.010 |
Why?
|
Oxides | 1 | 2004 | 210 | 0.010 |
Why?
|
Aminoglycosides | 1 | 2004 | 224 | 0.010 |
Why?
|
Arsenicals | 1 | 2004 | 201 | 0.010 |
Why?
|
Women's Health | 1 | 2004 | 213 | 0.010 |
Why?
|
Colonoscopy | 2 | 1996 | 524 | 0.010 |
Why?
|
Tretinoin | 1 | 2004 | 637 | 0.010 |
Why?
|
Nasal Cavity | 1 | 2003 | 150 | 0.010 |
Why?
|
Radiotherapy Dosage | 1 | 2009 | 3974 | 0.010 |
Why?
|
Carcinoma | 1 | 1992 | 2601 | 0.010 |
Why?
|
Research | 1 | 2003 | 436 | 0.010 |
Why?
|
Video Recording | 1 | 2002 | 279 | 0.010 |
Why?
|
Body Mass Index | 1 | 2008 | 2300 | 0.010 |
Why?
|
Prevalence | 1 | 2008 | 3402 | 0.010 |
Why?
|
Neoplasms | 1 | 2006 | 15713 | 0.010 |
Why?
|
Dermatologic Surgical Procedures | 1 | 2000 | 109 | 0.010 |
Why?
|
Case-Control Studies | 2 | 2001 | 6241 | 0.010 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2004 | 2273 | 0.010 |
Why?
|
Drug Administration Schedule | 1 | 2004 | 3517 | 0.010 |
Why?
|
Prostatic Neoplasms | 1 | 1996 | 5939 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2008 | 4550 | 0.010 |
Why?
|
Pancreas | 1 | 2001 | 735 | 0.010 |
Why?
|
Testicular Diseases | 1 | 1997 | 23 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2011 | 5715 | 0.010 |
Why?
|
Ileocecal Valve | 1 | 1996 | 3 | 0.010 |
Why?
|
Pancreatectomy | 1 | 2001 | 681 | 0.010 |
Why?
|
Cholangiography | 1 | 1996 | 36 | 0.010 |
Why?
|
Ileal Diseases | 1 | 1996 | 29 | 0.010 |
Why?
|
Bronchography | 1 | 1996 | 25 | 0.010 |
Why?
|
Cholelithiasis | 1 | 1996 | 46 | 0.010 |
Why?
|
Intussusception | 1 | 1996 | 53 | 0.010 |
Why?
|
Palpation | 1 | 1996 | 52 | 0.010 |
Why?
|
Sarcoidosis, Pulmonary | 1 | 1995 | 21 | 0.010 |
Why?
|
Sternum | 1 | 1996 | 102 | 0.010 |
Why?
|
HIV Antibodies | 1 | 1995 | 110 | 0.010 |
Why?
|
Lymphatic Diseases | 1 | 1995 | 130 | 0.010 |
Why?
|
Muscular Diseases | 1 | 1995 | 162 | 0.010 |
Why?
|
Bile Ducts, Intrahepatic | 1 | 1996 | 339 | 0.010 |
Why?
|
Sheep | 1 | 1994 | 266 | 0.010 |
Why?
|
Postpartum Period | 1 | 1995 | 265 | 0.010 |
Why?
|
Duodenum | 1 | 1994 | 154 | 0.010 |
Why?
|
Prednisone | 1 | 1996 | 997 | 0.010 |
Why?
|
Thorax | 1 | 1994 | 219 | 0.010 |
Why?
|
Antibodies, Monoclonal, Humanized | 1 | 2004 | 3362 | 0.010 |
Why?
|
Actuarial Analysis | 1 | 1992 | 165 | 0.010 |
Why?
|
Hospitals, General | 1 | 1992 | 27 | 0.010 |
Why?
|
Fatal Outcome | 1 | 1995 | 834 | 0.010 |
Why?
|
Massachusetts | 1 | 1992 | 124 | 0.010 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 1995 | 365 | 0.010 |
Why?
|
Graft Survival | 1 | 1996 | 1094 | 0.010 |
Why?
|
Peripheral Nervous System Diseases | 1 | 1996 | 398 | 0.010 |
Why?
|
Colon | 1 | 1996 | 677 | 0.010 |
Why?
|
Immunocompromised Host | 1 | 1996 | 709 | 0.010 |
Why?
|
Ultrasonography, Prenatal | 1 | 1997 | 849 | 0.010 |
Why?
|
Antibodies, Monoclonal | 1 | 2004 | 4453 | 0.010 |
Why?
|
Respiration, Artificial | 1 | 1994 | 591 | 0.010 |
Why?
|
Gastric Mucosa | 1 | 1994 | 623 | 0.010 |
Why?
|
Cross Infection | 1 | 1994 | 551 | 0.010 |
Why?
|
Transplantation, Homologous | 1 | 1996 | 2946 | 0.010 |
Why?
|
Delivery of Health Care | 1 | 1996 | 885 | 0.010 |
Why?
|
Logistic Models | 1 | 1996 | 3517 | 0.010 |
Why?
|
Adipose Tissue | 1 | 1993 | 775 | 0.000 |
Why?
|
Spinal Cord | 1 | 1990 | 702 | 0.000 |
Why?
|
Incidence | 1 | 1996 | 5890 | 0.000 |
Why?
|
Liver | 1 | 1995 | 2987 | 0.000 |
Why?
|
Hypertension | 1 | 1994 | 1585 | 0.000 |
Why?
|
Registries | 1 | 1992 | 2289 | 0.000 |
Why?
|
Smoking | 1 | 1993 | 2526 | 0.000 |
Why?
|
Child | 2 | 1996 | 30138 | 0.000 |
Why?
|
Infant, Newborn | 1 | 1997 | 8543 | 0.000 |
Why?
|
Survival Analysis | 1 | 1992 | 9323 | 0.000 |
Why?
|
Animals | 1 | 1994 | 60992 | 0.000 |
Why?
|